VitaSynth Sp. z o.o.
About
Company description
lt's been almost 10 years since the last new synthesis path for Menaquinone-7 has been commercialised. The wait was undoubtedly worthwhile.
Now VitaSynth is challenging the market with its second-generation synthesis technology. Capitalising on our 12 years of experience in manufacturing and elementary research, we proudly bring in Pharmaquinone® range of Vitamin K2 actives and dilutions.Europharma logoVitasynth logo
Our Journey
2006 Vitamin K2 introductory meetings at Vitafoods Geneva between Nattopharma ASA and EuroPharma Alliance
2007 EuroPharma Alliance becomes sole distributor of Nattopharma in Central East Europe
2008 MK-7 synthesis discussions at SupplySide West, Las Vegas between EuroPharma Alliance and Syntavit AS, future Kappa Bioscience AS
2009 VitaSynth (a sister company to EuroPharma Alliance) is incorporated and signs MK-7 synthesis development agreement with an academic partner
2012 VitaSynth fills first-generation synthesis patent
2013 VitaSynth sells the patent to Nattopharma ASA, retains the manufacturing rights
2017 VitaSynth moves commercial production of vitamin K2 to own facility
2020 VitaSynth fills second generation synthesis patent
2021 Pharmaquione range is launched globally at Vitafoods Geneva
